Clinical Trials Browser

avapritinib × Other hematologic neoplasm × 90 days × Clear all

NCT03580655 2026-04-24

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

Phase 2 Completed

107 enrolled 30 charts 1 FDA

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT06327685 2026-04-01

Avapritinib With Decitabine in Patients With SM-AHN

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Systemic Mastocytosis With an Associated Hematologic Neoplasm